Oncternal Fast Track for Treatment of Metastatic Castration-Resistant Prostate Cancer

 Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting androgen receptor inhibitor (DAARI), as a Fast Track development program for the investigation of the treatment of patients with relapsed or refractory metastatic castration-resistant prostate cancer (mCRPC) resistant to approved androgen receptor pathway inhibitors (ARPIs).

https://www.globenewswire.com/news-release/2023/10/26/2767604/0/en/Oncternal-Therapeutics-Announces-FDA-Granted-Fast-Track-Designation-for-ONCT-534-for-the-Treatment-of-Metastatic-Castration-Resistant-Prostate-Cancer.html